---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-056109"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2026-05-14T00:35:37+00:00"
generated_at: "2026-05-14T10:15:24.130063+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Onconetix reports Q1 2026 progress: two Proclarix publications, PRIME study with Labcorp, European expansion

## Summary
- Two peer-reviewed papers published: Schiess et al. in BMC Cancer (371 men) and Athanasiou et al. in Cancers (132 men) reinforce Proclarix performance in reducing unnecessary biopsies.
- PRIME multi-center clinical study initiated with Labcorp; first participants enrolled, targeting up to 500 men for U.S. validation.
- European commercial expansion: ~100 Proclarix tests performed in UK screening initiative in Q1 2026; collaboration partner identified in Turkey.
- Proclarix is a CE-IVD certified blood test for identifying clinically significant prostate cancer, designed to reduce overdiagnosis.

## SEC filing metadata
- accession: 0001213900-26-056109
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2026-05-14T00:35:37+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390026056109/0001213900-26-056109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390026056109/ea0290739-8k_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-056109
- JSON: https://secwatch.observer/filing/0001213900-26-056109.json
- Plain text: https://secwatch.observer/filing/0001213900-26-056109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.